FTC drops offense on Defense
This article was originally published in The Tan Sheet
Executive SummaryThe Federal Trade Commission decides not to pursue investigations into health claims substantiation for Prestige Brands' Chloraseptic Defense Daily Health Strips and Insight Pharmaceuticals' Sucrets Defense lozenges in part because both products have been permanently discontinued, FTC states in June 1 letters to the companies. The Chloraseptic Defense strips claimed to boost the immune system and prevent flu and cold. Similarly, Sucrets Defense claimed to boost the immune system and fight colds as well as provide protection before entering crowded places. Other factors leading to FTC's decisions to not pursue the investigations include the short periods of time the products were marketed, the limited nature of the products' ad campaigns and relatively small resulting sales, FTC states...
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.